AstraZeneca Pharma India Limited, a leading science-led biopharmaceutical company received the government’s approval for Dapagliflozin (Forxiga), for the treatment of patients with heart failure on Tuesday. This is the first antidiabetic drug approved for the treatment of heart failure (HF) and is the first drug proven to reduce the risk of Cardiovascular death and hospitalisation.
The approval is based on the results from the DAPA-HF study, that proved that Forxigain addition to standard of care, reduced the risk of Cardiovascular death or the worsening of Heart Failure by 26%.About one-fourth patients in the study population were from Asian region including India.
Dapaglifozin (Forxiga) is also indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in India. The drug is also approved for reduction of risk of hospitalisation due to Heart failure in type 2 diabetes patients with high risk factors.